In 2018, there is no shortage of treatments available to address migraines. Some of the top migraine treatments for 2018 include:
- Monoclonal Antibodies
Late-stage drug trials recently highlighted the potential of monoclonal antibodies, proteins that target harmful substances in the body. These antibodies may be used to target calcitonin gene-related peptide (CGRP), a molecule that plays a role in migraines.
To date, researchers have studied several monoclonal antibodies and their impact on CGRP. These antibodies include:
- AMG 334: Targets the CGRP receptor rather than CGRP itself; AMG 334 has been studied in nonhuman primates and is currently being tested in phase II clinical trials for the prevention of migraines.
- LY2951742: Helps decrease the number of migraine headache days, migraine attacks and probable migraine and migraine headache days.
- ALD403: Helps reduce or eliminate migraines and migraine days.
Migraine patients have displayed no adverse effects following clinical studies involving the aforementioned monoclonal antibodies, according to Neurology Reviews. Additionally, studies have shown there are no safety concerns associated with these monoclonal antibodies relative to migraine treatments.
Erenumab is a human monoclonal antibody that may prove to be an effective long-term migraine treatment. In fact, The New England Journal of Medicine reported a clinical trial of erenumab injections showed the antibody may be used to help prevent migraines.
In the clinical trial, migraine patients who were given between 70 and 140 mg of erenumab saw a reduction in migraine frequency, the effects of migraines on daily activities and their use of acute migraine-specific medications. However, researchers indicated they require additional clinical trials to determine the long-term safety of erenumab for migraines.
BOTOX® helps stop migraines before they start. It is a neurotoxin derived from Clostridium botulinum bacteria and can be injected into the skin to temporarily prevent nerve cell signals from reaching the facial muscles. When this occurs, BOTOX® relaxes the muscles and reduces abnormal muscle contraction that sometimes causes migraines.
A typical BOTOX® for migraine treatment program requires two treatments approximately 12 weeks apart. After the initial 12 weeks, a migraine patient can determine whether BOTOX® is delivering the desired results.
On average, BOTOX® injections prevent eight to nine headache days and migraine or probable migraine days per month at 24 weeks. A BOTOX® treatment generally takes about 15 minutes to administer, and regular BOTOX® treatments may help a migraine sufferer reduce or eliminate migraine pain in 2018 and beyond.
- Migraine Surgery
Minimally invasive surgery offers a safe, effective option to treat migraines. It involves the use of advanced migraine decompression techniques to address a patient’s migraine triggers. As a result, surgery often helps a migraine patient permanently remove faulty nerve signals that cause migraines.
Clearly, there are lots of options available to help individuals address their migraine symptoms. Thanks to The Migraine Institute, individuals can receive in-depth migraine treatments designed to provide long-lasting migraine pain relief.
Dr. Jonathan Cabin of the Migraine Institute administers BOTOX® and migraine surgery treatments. He helps individuals who have received a chronic migraine diagnosis from a neurologist and find their current migraine medications fail to deliver the optimal results or cause intolerable side effects. To find out more about our migraine treatment options, please contact us today at 310.461.0303 to schedule a consultation.